NewVale Capital
NewVale Capital is a sector-specialist growth equity firm investing $10M–$50M equity checks into proven, revenue-generating ($5M–$50M+) life sciences services and enabling technology companies across drug discovery, clinical research, manufacturing, and commercialization, managing over $2 billion across 40 platform investments.
- Company typePrivate
- Founded2021
- HeadquartersBoulder, United States
- Headcount1–10
- GTM typeB2B
- OfferingServices
What NewVale Capital does
NewVale Capital is a sector-specialist growth equity firm founded in 2021 by Todd Holmes that invests exclusively in the "services architecture" behind the life sciences industry — the outsourced services and enabling technology businesses serving pharmaceutical and biotechnology customers across the drug development and commercialization value chain. The firm is headquartered in Boulder, Colorado with a New York office, operates as an exempt reporting adviser under the U.S. Investment Advisers Act of 1940, and had assets under management exceeding $2 billion across 40 platform investments as of November 2025. Its investment thesis targets the structural funding gap between venture capital and traditional private equity, deploying $10M–$50M equity checks (flexible minority or majority) into commercially proven businesses with $5M–$50M+ of revenue organized across four subsector pillars: Drug Discovery, Clinical Research, Manufacturing & Supply Chain, and Commercialization.
The firm's product surface is a single managed growth equity fund — its oversubscribed $167 million debut vehicle, announced May 13, 2024 — supported by an "Ecosystem Hub" of Operating Partners, senior advisors, and strategic acquirers intended to source deals and accelerate portfolio company value creation. Named portfolio companies include Noxilizer ($30M growth investment led by NewVale, September 2025, in nitrogen dioxide terminal sterilization), Argonaut Manufacturing Services ($45M equity round co-led with Telegraph Hill Partners, March 2024, an aseptic fill/finish CDMO), Aizon ($20M Series C led by NewVale, February 2024, an AI-enabled GxP manufacturing software platform), and Beaconcure ($14M Series B, June 2023, an AI-enabled clinical data validation platform). Underlying technology infrastructure for the firm itself is limited to its corporate website and an Intralinks-based investor portal; NewVale does not operate proprietary technology products.
NewVale generates revenue through conventional fund economics — management fees on committed or invested capital plus carried interest on fund profits — rather than product or subscription sales. Distribution is relationship-driven rather than open-application: deal sourcing is led by the firm's investment team, its Operating Partner network of former pharma and CDMO executives, and direct outreach to life sciences services and enabling technology businesses in the $5M–$50M+ revenue band. Marketing and demand-generation channels are anchored on the firm's website, LinkedIn presence, and third-party press releases distributed via PR Newswire and Business Wire, with earned media in life sciences trade publications.
NewVale Capital firmographics
Firmographics- Name
- NewVale Capital
- Legal name
- NewVale Capital LLC
- Website
- https://newvalecapital.com
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- NewVale Capital is a sector-specialist growth equity firm investing $10M–$50M equity checks into proven, revenue-generating ($5M–$50M+) life sciences services and enabling technology companies across drug discovery, clinical research, manufacturing, and commercialization, managing over $2 billion across 40 platform investments.
- Ownership category
- akta.pro rank
NewVale Capital industry classification
Industry- Product category
- Growth Equity / Private Equity (Life Sciences Services)
- NAICS
- Investment Banking and Securities Intermediation (523150), Portfolio Management and Investment Advice (523940)
- SIC
- Security Brokers, Dealers & Flotation Companies (6211)
- akta.pro primary industry
- Healthcare & Life Sciences Growth Equity (FSANACAB)
- akta.pro secondary industries
- Equity Capital Advisory (Private Equity Placements, Growth Capital) (BPAHAOAE), Capital Raising Advisory (Equity & Equity-Linked) (FSAEAGAC)
Keywords
Where NewVale Capital is headquartered
LocationHeadquarters
- HQ city
- Boulder
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
NewVale Capital business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Others
Revenue model
- Investment returns from equity investments in portfolio companies: NewVale generates returns through equity investments of $10M to $50M per platform in life sciences services and technology companies. As a venture-style adviser relying on the VC fund adviser exemption, the firm invests in commercially proven businesses with $5M–$50M+ in revenue, taking flexible minority or majority positions and realizing value through growth, exit, or recapitalization events.
- Fund management fees and carried interest on managed capital: As an investment adviser managing pooled funds (debut fund of $167 million, with over $2 billion in assets under management as of November 2025), NewVale derives revenue from conventional fund economics — management fees on committed/invested capital and carried interest on fund profits — though specific fee terms are not publicly disclosed.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Equity investment check size of $10M to $50M per platform |
Go-to-market motion2 records
Distribution channels2 records
Marketing channels5 records
NewVale Capital product offering
Product offeringCore offering
NewVale Capital is a sector-specialist growth equity firm that deploys $10M–$50M equity checks into proven, revenue-generating ($5M–$50M+) life sciences services and enabling technology businesses via flexible minority or majority structures. Operating through a debut $167M oversubscribed fund and $2B+ in AUM, the firm invests across four defined subsectors—Drug Discovery, Clinical Research, Manufacturing & Supply Chain, and Commercialization—combining Flexible Capital, Scale Execution support, and an Ecosystem Hub of senior Operating Partners.
Product overview
NewVale Capital offers a single unified investment platform — the NewVale Capital Life Sciences Services Growth Equity Fund — organized around four dedicated investment subsector pillars (Drug Discovery, Clinical Research, Manufacturing & Supply Chain, and Commercialization) that together comprise its sector-specialist pharma services and enabling technology thesis. The fund deploys flexible capital (minority or majority, $10M–$50M equity checks) into commercially proven, revenue-generating businesses and supports them with three value-creation levers — Flexible Capital, Scale Execution, and Ecosystem Hub — to bridge the gap between commercial proof points and commercial scale. Selected portfolio companies operating within these subsectors include Aizon (AI-enabled GxP manufacturing software, Manufacturing & Supply Chain), Argonaut (aseptic fill/finish CDMO, Manufacturing & Supply Chain), Beaconcure (AI-enabled clinical data validation software, Clinical Research), and Noxilizer (NO2 terminal sterilization technology, Manufacturing & Supply Chain).
Differentiator
Problem solved
Functional benefit
Products and services
- NewVale Capital Life Sciences Services Growth Equity Fund A sector-specialist growth equity fund that provides right-sized equity capital of $10M to $50M per company to proven, revenue-generating ($5M to $50M+) life sciences services and enabling technology businesses via flexible minority or majority structures.
Quantifiable outcome
- $167 million oversubscribed debut fund dedicated to life sciences services
- +2 more outcomes
Companies that use NewVale Capital
Customer profileSegments5 records
Ideal customer profiles1 record
NewVale Capital technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
NewVale Capital partnerships and signals
Strategic signalScale indicators7 records
Recent moves6 records
Expansion highlights6 records
NewVale Capital competitors and assessment
Company assessmentDirect peers
- Ampersand Capital Partners: Sector-specialist private equity firm focused exclusively on life sciences and healthcare services, tools, and technology. Most directly comparable to NewVale given similar niche focus, mid-market equity checks, and operating value-creation model.
- Linden Capital Partners: Healthcare-focused private equity firm investing in middle-market pharma services, specialty pharma, and healthcare products businesses. Closely comparable mid-market healthcare PE strategy and check size range to NewVale's life sciences services thesis.
- Great Point Partners: Healthcare-specialist private equity firm focused on growth-stage healthcare products, services, and infrastructure companies. Comparable to NewVale in targeting growth equity investments in healthcare services with similar check sizes and operating support model.
- Avista Capital Partners: Healthcare-focused private equity firm investing in growth-stage healthcare services, pharmaceutical, and medical products businesses. Directly comparable sector focus and mid-market growth equity strategy.
- Arsenal Capital Partners: Specialist private equity firm focused on healthcare and specialty industrials, with deep pharma services investing experience. Comparable mid-market healthcare PE thesis; NewVale principal Melanie Larkins previously worked at Arsenal.
- Telegraph Hill Partners: Life sciences and healthcare-focused growth equity firm investing in commercial-stage life sciences companies. Directly comparable to NewVale; co-invested with NewVale in Argonaut Manufacturing Services in March 2024.
- Gurnet Point Capital: Healthcare-focused investment firm with strong life sciences services and pharma sector orientation. Highly comparable given that NewVale's founder Todd Holmes and executive partner Patrick Lee both previously held senior investment roles there.
Broad incumbents
- HealthCare Royalty Partners: Healthcare-specialist investment firm with broader mandate across healthcare royalties, structured finance, and growth equity. Comparable life sciences sector focus, though business model extends beyond traditional growth equity.
- Blackstone Life Sciences: Large-scale life sciences investment platform within Blackstone, investing across pharma services, royalty, and drug development. Comparable life sciences services focus, but with materially larger capital base and broader strategy.
- Bain Capital Life Sciences: Specialist life sciences investment platform of Bain Capital, focused on pharma services and biotech. Comparable sector specialization, though operating at significantly larger fund size than NewVale's debut vehicle.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
NewVale Capital social profiles
Digital presenceNewVale Capital financial estimates
Financial estimateRevenue estimate
Valuation estimate
NewVale Capital leadership team
Management profileNumber of profiles
Profiles12 records
NewVale Capital funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
NewVale Capital M&A and investment
M&A and investmentM&A
Investments5 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about NewVale Capital
What does NewVale Capital do?
NewVale Capital is a sector-specialist growth equity firm that deploys $10M–$50M equity checks into proven, revenue-generating ($5M–$50M+) life sciences services and enabling technology businesses via flexible minority or majority structures. Operating through a debut $167M oversubscribed fund and $2B+ in AUM, the firm invests across four defined subsectors—Drug Discovery, Clinical Research, Manufacturing & Supply Chain, and Commercialization—combining Flexible Capital, Scale Execution support, and an Ecosystem Hub of senior Operating Partners.
Is NewVale Capital a public or private company?
NewVale Capital is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was NewVale Capital founded?
NewVale Capital was founded in 2021. It employs 1 to 10 people.
Where is NewVale Capital based?
NewVale Capital is headquartered in Boulder, United States, in the North America region.
How does NewVale Capital make money?
Two revenue lines are on record. Investment returns from equity investments in portfolio companies are the primary driver. The others are fund management fees and carried interest on managed capital.
Who are NewVale Capital's main competitors?
Direct peers on record are Ampersand Capital Partners, Linden Capital Partners, Great Point Partners, Avista Capital Partners, Arsenal Capital Partners, Telegraph Hill Partners and Gurnet Point Capital. Broad incumbents are HealthCare Royalty Partners, Blackstone Life Sciences and Bain Capital Life Sciences.
Does NewVale Capital have an API?
No public API is recorded for NewVale Capital.
What industry is NewVale Capital in?
NewVale Capital's product category is Growth Equity / Private Equity (Life Sciences Services). Its primary akta.pro industry code is FSANACAB, Healthcare & Life Sciences Growth Equity, with a secondary code of BPAHAOAE, Equity Capital Advisory (Private Equity Placements, Growth Capital). Its NAICS code is 523150 and its SIC code is 6211.